無痛性非ホジキンリンパ腫患者の治療のための単剤療法および併用療法としての新規ワクチン (EO2463) (SIDNEY)
無痛性非ホジキンリンパ腫患者の治療のための、単剤療法としての、またレナリドマイドおよびリツキシマブとの併用療法としての新規微生物由来ペプチド治療用ワクチンであるEO2463のグローバル多施設第1/2相試験
The purpose of this study is to define the recommended Phase 2 Dose, safety, tolerability, immunogenicity, and preliminary efficacy of EO2463 during monotherapy and in combination with lenalidomide and/or rituximab in patients with indolent NHL
調査の概要
詳細な説明
EO2463 Is an innovative cancer peptide therapeutic vaccine based on the homologies between tumor associated antigens and microbiome-derived peptides that will be administered alone and in combination with lenalidomide, rituximab, and lenalidomide/rituximab to generate safety and preliminary efficacy data in patients with indolent NHL
研究の種類
入学 (推定)
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02215
- Dana Farber Cancer Institute
-
-
Minnesota
-
Rochester、Minnesota、アメリカ、55905
- Mayo Clinic
-
-
New York
-
Rochester、New York、アメリカ、14642
- University of Rochester Medical Center (URMC) - Wilmot Cancer Institute (WCI) (James P. Wilmot Cancer Center)
-
-
Washington
-
Seattle、Washington、アメリカ、98109
- University of Washington-Seattle Cancer Care Alliance
-
-
-
-
-
Naples、イタリア
- IRCCS Policlinico San Matteo Foundation - University of Pavia
-
Pavia、イタリア
- IRCCS Policlinico San Matteo Foundation - University of Pavia
-
-
-
-
-
Barcelona、スペイン
- University Hospital Vall d'Hebron, Institute of Oncology
-
Madrid、スペイン
- Clinica Universidad de Navarra
-
Pamplona、スペイン
- Clinica Universidad de Navarra
-
Salamanca、スペイン
- Hospital Clinico Universitario de Salamanca
-
-
-
-
-
Amiens、フランス
- CHU d'Amiens-Picardie - Hopital SUD
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- For inclusion in Cohorts 1 and 4 patients should have relapsed/refractory, biopsy-proven grade 1, 2 or 3A, FL or MZL, ECOG performance status 0 to 2, and have received at least one prior line of treatment. For inclusion in Cohort 4b the above applies except that patients with FL, and not patients with MZL, will be eligible for enrollment.
- For inclusion in Cohort 2 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-proven grade 1, 2 or 3A, FL or MZL. ECOG performance status 0 or 1, low tumor burden by Groupe d'Etude des Lymphomes Folliculaires (GELF) criteria, and not be in need of standard of care therapy according to the assessment of the treating physician.
- For inclusion in Cohort 3 patients should have newly diagnosed, previously untreated (radiotherapy as only prior treatment is allowed), biopsy-proven grade 1, 2 or 3A, FL or MZL. ECOG performance status 0 or 1, low tumor burden by GELF criteria and be in need of therapy according to the assessment of the treating physician.
- Patients with an age ≥ 18 years old.
- Patients who are human leukocyte antigen (HLA)-A2 positive.
- Patients should have radiologically measurable disease with a lymph node or tumor mass greater than or equal to 1.5 cm in at least one dimension.
- Males or non-pregnant, non-lactating, females.
- Patients willing and able to comply with the scheduled visits, treatment plan, laboratory tests, and other study procedures indicated in the protocol.
- Patients having received the information sheet and who have provided written informed consent prior to any study-related procedures.
Exclusion Criteria:
- Patients treated with dexamethasone > 2 mg/day or equivalent (i.e. 13 mg/day of prednisone, or 53 mg/day of hydrocortisone) within 14 days before the first EO2463 administration, unless required to treat an adverse event.
- Patients with grade 3B FL or transformation to an aggressive lymphoma subtype.
- Patients with only one prior treatment and a high-risk profile as defined by first progression of disease within 24 months of diagnosis (the exclusion is not applicable for patients with more than one prior line treatment).
- Patients with prior exposure to EO2463.
- Patients treated with immunotherapy (meaning immunostimulatory or immunosuppressive therapy; beside excluded, or allowed, compounds per other inclusion/exclusion criteria specifications), radionuclide therapy, radiotherapy, cytoreductive therapy, or received treatment with any other investigational agent within 28 days before the first EO2463 administration.
- Patients to be included in Cohorts 1 and 4, and who have received rituximab or other B cell ablation therapy within 8 weeks of start of study treatment.
- Patients to be included in Cohorts 4, who received prior CAR T-cell therapy and progressed within 6 months after this therapy.
- Patients with abnormal laboratory values.
- Patients with persistent Grade 3 or 4 toxicities.
- Uncontrolled central nervous system (CNS) metastasis.
- Other malignancy or prior malignancy with a disease-free interval of less than 3 years.
- Patients with clinically significant disease.
- Patients with suspected autoimmune or active autoimmune disorder or known history of an autoimmune neurologic condition (e.g. Guillain-Barré syndrome).
- Patients with history of solid organ transplantation or allogeneic hematopoietic stem cell transplantation.
- Pregnant and breastfeeding patients.
- Patients with history or presence of human immunodeficiency virus and/or potentially active hepatitis B virus/hepatitis C virus infection.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:順次割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:Cohort 1
Safety Lead-In, Dose-Finding, Cohort, with a 3-by-3 design of EO2463 monotherapy for 6 weeks followed by addition of lenalidomide. Then, if applicable rituximab (depending on response with EO2463 + lenalidomide) will be added. Four to 18 previously treated patients with Follicular Lymphoma (FL) or Marginal Zone Lymphoma (MZL) were anticipated to be included based on safety findings. |
Multiple dose of EO2463 D1-21 of 4-weekly cycles
他の名前:
Multiple doses of rituximab
他の名前:
|
|
実験的:Cohort 2
Anticipated approximatively 25 previously untreated patients with FL or MZL with an evaluation of EO2463 monotherapy (at the established dose in Cohort 1). |
Multiple dose of EO2463 |
|
実験的:Cohort 3
Anticipated approximatively 6 previously untreated patients with FL or MZL with an evaluation of EO2463 (at the established dose in cohort 1) as monotherapy for 6 weeks followed by addition of rituximab if applicable (depending on response with EO2463 monotherapy). |
Multiple dose of EO2463 Multiple doses of rituximab
他の名前:
|
|
実験的:Cohort 4
Anticipated approximatively 40 patients previously treated patients with FL (or MZL). Evaluation of EO2463 (at the established dose in Cohort 1) in combination with lenalidomide from day 1 and then with addition of rituximab. |
Multiple dose of EO2463 D1-21 of 4-weekly cycles
他の名前:
Multiple doses of rituximab
他の名前:
|
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Phase 1: Recommended Phase 2 Dose | Adverse Events Assessment |
時間枠:Up to 24 months
|
Incidences of adverse events, Treatment-Emergent Adverse events, Serious Adverse Events, Deaths, and Laboratory Abnormalities Using the National Cancer Institute-Common Terminology Criteria for Adverse events (NCI-CTCAE) V5.0. |
Up to 24 months
|
|
Phase 2: Overall Response Rate
時間枠:Up to 24 months
|
Overall Response Rate According to the Lugano Classification 2014 during EO2463 Monotherapy |
Up to 24 months
|
|
Phase 2: Complete Response Rate
時間枠:Up to 24 months
|
Complete remission (CR)-rate according to the Lugano Classification 2014 during therapy with the combination of EO2463/lenalidomide/rituximab. |
Up to 24 months
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Assessment of the Immunogenicity in Relation to OMP72, OMP64, OMP65, OMP66, and UCP2 that Compose EO2463
時間枠:Up to 24 months
|
Immunogenicity will be assessed by interferon-Gamma (IFN-Γ) enzyme-Linked immunospot , and/or by intracellular cytokines staining, and/or multimers staining assays. |
Up to 24 months
|
|
Evaluation of Overall Survival
時間枠:Up to 7 years after last patient enrolled
|
The time interval from the date of first study treatment administration to the date of death due to any cause |
Up to 7 years after last patient enrolled
|
協力者と研究者
スポンサー
捜査官
- スタディディレクター:Jan Fagerberg, MD、Enterome
研究記録日
主要日程の研究
研究開始 (実際)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
- 新生物
- 免疫系疾患
- 組織型別の新生物
- リンパ疾患
- リンパ増殖性疾患
- 免疫増殖性疾患
- リンパ腫、非ホジキン
- リンパ腫、B細胞
- リンパ腫
- ヘミックおよびリンパ疾患
- リンパ腫、濾胞性
- リンパ腫、B細胞、辺縁帯
- アミノ酸、ペプチド、およびタンパク質
- タンパク質
- 有機化学物質
- 複素環化化合物、1リング
- 複素環化化合物
- 複素環化化合物、2リング
- 複素環化化合物、融合リング
- カルボン酸
- ピペリジン
- 抗体、モノクローナル
- 抗体
- 免疫グロブリン
- 免疫タンパク質
- 血液タンパク質
- 血清グロブリン
- グロブリン
- 抗体、モノクローナル、マウス由来
- フタリミド
- フタル酸
- 酸、炭素環
- ピペリドン
- イソインドール
- レナリドミド
- リツキシマブ
その他の研究ID番号
- EONHL1-20
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
米国で製造され、米国から輸出された製品。
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。